<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03314324</url>
  </required_header>
  <id_info>
    <org_study_id>2017-001606-14</org_study_id>
    <secondary_id>2017/2555</secondary_id>
    <nct_id>NCT03314324</nct_id>
  </id_info>
  <brief_title>A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer</brief_title>
  <acronym>ODENZA</acronym>
  <official_title>A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess patient preference between ODM-201 and enzalutamide by patient preference&#xD;
      questionnaire&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, open-label, multicenter, cross-over phase II trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient preference</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Patient preference (assessed by a single question) between ODM-201 and enzalutamide after completion of the second period of treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Metastatic Castrate-resistant Prostate (CRPC) Cancer</condition>
  <arm_group>
    <arm_group_label>ODM-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODM-201</intervention_name>
    <description>ODM-201: 600 mg (2 x 300 mg tablets) twice daily with food equivalent to a total daily dose of 1200 mg. ODM-201 should be taken at similar times day, approximately 12 hours between doses.</description>
    <arm_group_label>ODM-201</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Enzalutamide: 160 mg/day (4 x 40 mg tablets) taken once a day preferably with food, preferably in the evening (Enzalutamide can generally be given with or without food, but in the present trial, it is preferable that it is given with food, to be consistent with ODM-201 intake).</description>
    <arm_group_label>Enzalutamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male patients older than 18 years&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Evidence of metastatic disease (imaging can include bon scan, CT scan, PET choline,&#xD;
             PET PSMA and MRI)&#xD;
&#xD;
          -  Continued androgen deprivation therapy (ADT) either with LHRH agonists/antagonists or&#xD;
             bilateral orchiectomy&#xD;
&#xD;
          -  Serum testosterone &lt;0.50 ng/ml (1.7 nmol/L)&#xD;
&#xD;
          -  Progressive disease (PSA progression or radiological progression or clinical&#xD;
             progression) as per PCWG3 criteria&#xD;
&#xD;
          -  ECOG 0-1 (2 is accepted if the impairement is not due to prostate cancer)&#xD;
&#xD;
          -  Asymptomatic or mildly symptomatic prostate cancer as measured on the Brief Pain&#xD;
             Inventory Short Form question 3 (i.e. worst pain in the last 24 hours &lt;4 on a Visual&#xD;
             Analog Scale)&#xD;
&#xD;
          -  Information imparted to the patient and the informed consent form signed by the&#xD;
             patient or his legal representative&#xD;
&#xD;
          -  Ability to comply with the protocol procedures&#xD;
&#xD;
          -  Patient affiliated to a social security system or beneficiary of the same&#xD;
&#xD;
          -  Sexually active male subjects unless surgically sterile, must agree to use condoms as&#xD;
             an effective barrier method and refrain from sperm donation, and/or their female&#xD;
             partners of reproductive potential to use a method of effective birth control, during&#xD;
             the study treatment and for 3 months after the end of the treatment&#xD;
&#xD;
          -  adequate organ or bone marrow function as evidenced by:&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1.5 x 109/L,&#xD;
&#xD;
          -  Platelet count ≥ 100 x 109/L, (subject must not have received any growth factor within&#xD;
             4 weeks or blood transfusion within 7 days of the hematology laboratory sample&#xD;
             obtained at screening)&#xD;
&#xD;
          -  AST/SGOT and/or ALT/SGPT ≤1.5 x ULN;&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x ULN, (except subjects with a diagnosis of Gilbert's disease),&#xD;
&#xD;
          -  Serum creatinine ≤ 2 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will&#xD;
             be calculated according to the CKDEPI formula and patients with creatinine clearance&#xD;
             &lt;60 mL/min should be excluded.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with abiraterone, enzalutamide, ODM-201, ARN- 509 or any other&#xD;
             next-generation AR axis-targeting drug&#xD;
&#xD;
          -  Prior treatment with a taxane for CRPC (prior treatment with a taxane for&#xD;
             castration-sensitive or castration-naïve prostate cancer is allowed)&#xD;
&#xD;
          -  Prior treatment with radium-223&#xD;
&#xD;
          -  Patients receiving an investigational drug within 4 weeks prior to enrolment (approved&#xD;
             drugs with a long history of use such as aspirin, statins, heparins, or metformin,&#xD;
             even used in an experimental setting are accepted)&#xD;
&#xD;
          -  Treatment with radiotherapy (external beam radiation therapy [EBRT], brachytherapy, or&#xD;
             radiopharmaceuticals) within 2 weeks before randomization&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs, study drug classes, or excipients in&#xD;
             the formulation of the study drugs&#xD;
&#xD;
          -  Acute toxicities of prior treatments and procedures not resolved to grade &lt;=1 or&#xD;
             baseline before randomisation.&#xD;
&#xD;
          -  Had any of the following within 6 months before randomization: stroke, myocardial&#xD;
             infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft,&#xD;
             congestive heart failure (New York Heart Association (NYHA) Class III or IV)&#xD;
&#xD;
          -  Uncontrolled hypertension as indicated by a resting systolic blood pressure (BP) ≥160&#xD;
             mmHg or diastolic BP ≥100 mmHg despite optimal medical management&#xD;
&#xD;
          -  Had a prior malignancy. Adequately treated basal cell or squamous cell carcinoma of&#xD;
             skin or superficial bladder cancer that has not spread behind the connective tissue&#xD;
             layer (i.e., pTis, pTa, and pT1) is allowed, as well as any other cancer for which&#xD;
             treatment has been completed ≥5 years before randomization and from which the subject&#xD;
             has been disease-free&#xD;
&#xD;
          -  A gastrointestinal disorder or procedure which is expected to interfere significantly&#xD;
             with absorption of study treatment&#xD;
&#xD;
          -  An active viral hepatitis, active human immunodeficiency infection(HIV), or chronic&#xD;
             liver disease with a need for treatment.&#xD;
&#xD;
          -  Any other serious or unstable illness or infection, or medical, social, or&#xD;
             psychological condition, that could jeopardize the safety of the subject and/or his&#xD;
             compliance with study procedures, or may interfere with the subject's participation in&#xD;
             the study or evaluation of the study results&#xD;
&#xD;
          -  Inability to swallow oral medications&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim FIZAZI, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

